| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, m-PEG2-O-Ph-3-NH2 itself has no intrinsic biological activity; it serves as a structural connector to join a target protein ligand and an E3 ubiquitin ligase ligand in PROTAC synthesis. The terminal primary amine (meta to the PEG chain) can be conjugated to a carboxylic acid-containing ligand via amide bond formation using EDC/NHS or HATU. The PEG2 spacer provides a short, hydrophilic, and flexible connection, while the phenyl ring introduces aromaticity, which can contribute to pi-pi stacking interactions with aromatic residues on the target protein or E3 ligase, potentially improving binding affinity. The meta-substitution may position the amine at a different angle compared to para, affecting conjugation geometry. The methoxy group is inert. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95%. The phenyl group can be characterized by its aromatic proton signals in NMR (around 6.8-7.4 ppm). The meta-substitution pattern can be confirmed by the splitting pattern of the aromatic protons. The primary amine can be quantified by titration.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical conjugation step, the primary amine is reacted with a carboxylic acid-containing ligand (e.g., an E3 ligase ligand or a target protein ligand) using EDC and NHS. The resulting PROTAC is then tested in target-expressing cells for degradation activity by Western blotting to determine the DC50. The meta-substitution may provide a different spatial orientation of the conjugated ligand compared to para, which could be beneficial for certain target-E3 ligase pairs.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete PROTAC conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated using a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via intraperitoneal (IP) or intravenous (IV) injection. The PEG2 spacer and meta-phenyl ring may affect the pharmacokinetic properties of the conjugate.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 211.26, a molecular formula of C11H17NO3, and a standard purity of ≥95%. The IUPAC name is 2-(2-(3-aminophenoxy)ethoxy)ethanol. For storage, it should be kept at -20degC for up to 3 years, sealed, away from moisture. It is soluble in DMSO and other organic solvents. CAS: 126415-02-9.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The product is stable under recommended storage conditions. It is not an approved therapeutic drug and has not been cleared for clinical use. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
|
| References | |
| Additional Infomation |
The meta-substituted aniline derivative provides a different conjugation geometry compared to the para isomer. This can be exploited in PROTAC design to fine-tune the orientation of the conjugated ligand relative to the phenyl ring and the PEG spacer. The aromatic ring can also participate in pi-pi stacking interactions with target proteins or E3 ligases, potentially improving degradation potency. This linker is a valuable building block for introducing an aromatic handle with a specific substitution pattern into PROTAC molecules.
|
| Molecular Formula |
C11H17NO3
|
|---|---|
| Molecular Weight |
211.26
|
| Exact Mass |
211.12
|
| CAS # |
126415-02-9
|
| PubChem CID |
43174403
|
| Appearance |
Light yellow to yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
346.2±27.0 °C at 760 mmHg
|
| Flash Point |
173.9±17.4 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.521
|
| LogP |
0.14
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
15
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCCOCCOC1=CC=CC(=C1)N
|
| InChi Key |
DEOFYPCJGRLJKB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H17NO3/c1-13-5-6-14-7-8-15-11-4-2-3-10(12)9-11/h2-4,9H,5-8,12H2,1H3
|
| Chemical Name |
3-[2-(2-methoxyethoxy)ethoxy]aniline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7335 mL | 23.6675 mL | 47.3350 mL | |
| 5 mM | 0.9467 mL | 4.7335 mL | 9.4670 mL | |
| 10 mM | 0.4734 mL | 2.3668 mL | 4.7335 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
